March 25 (Reuters) – Britain’s medicines regulator said on Wednesday it will introduce a framework by the end of 2026, which would allow drugmakers to ask a review of the data for drugs being developed without animal testing before applying for approval.
The draft guidance from the UK’s Medicines and Healthcare products Regulatory Agency aims to reduce reliance on animal studies and aligns with a broader global push to limit such testing in drug development.
Here are key details of the MHRA’s draft:
(Reporting by Rishab Shaju and Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri)
